Esquivel J, Farinetti A, Sugarbaker P H
Washington Cancer Institute, USA.
G Chir. 1999 Mar;20(3):81-6.
Peritoneal carcinomatosis occurs in about 10% of patients with colon cancer. Patients with progressive disease develop complications, with a median survival of 9 months. Our goal is to present a new quantitative scoring system by which to evaluate patients with peritoneal carcinomatosis. The Peritoneal Cancer Index and Completeness of Cytoreduction Score represent quantitative and prognostic indicators that permit the creation of a clinical pathway. Based on the scores, patients can undergo systemic chemotherapy, exploratory laparotomy or cytoreductive surgery. If there is a complete cytoreduction, perioperative intraperitoneal chemotherapy is given and these patients are considered potential long-term survivors.
约10%的结肠癌患者会发生腹膜癌转移。疾病进展的患者会出现并发症,中位生存期为9个月。我们的目标是提出一种新的定量评分系统,用以评估腹膜癌转移患者。腹膜癌指数和细胞减灭术完成度评分是定量和预后指标,可据此制定临床路径。根据这些评分,患者可接受全身化疗、剖腹探查术或细胞减灭术。如果实现了完全细胞减灭,则给予围手术期腹腔内化疗,这些患者被视为潜在的长期存活者。